MetLife, Inc. (MET) Down 4.7% — Time to Wave the White Flag?
MetLife, Inc. (MET) gave back a sharp slice of its recent gains on Friday, closing at $98.74 on the NYSE — a $4.83 decline from the prior close of $103.57. The timing makes the drop stand out. Just one session earlier, on October 22, 2026, the stock set a 52-week high of $103.65. Friday's close leaves MET about 4.7% below that peak, so a single session erased much of the progress that had carried the shares to their best level of the year.
Volume reached approximately 4.03 million shares, compared with a 90-day average of roughly 3.46 million. That is about 16% above normal. Selling was heavier than usual, but the turnover was not extreme for a decline of this size.
Why MetLife, Inc. Price is Moving Lower
The most plausible driver is a broad risk-off session that hit insurers especially hard. The insurance sector fell 2.12% on October 23. Losses spread across the group, with Manulife Financial Corporation (MFC) down 2.98%, The Allstate Corporation (ALL) down 2.28%, Chubb (CB) down 1.95%, and Arthur J. Gallagher (AJG) down 1.25%. The wider market was under strain as well. Brent crude was up 3.6% to $117.20 and the 10-year Treasury yield was at 4.99%, which pointed to inflation and rate worries weighing on stocks generally.
Insurer sentiment was already fragile heading into Friday. On October 21, Globe Life (GL) reported Q3 operating EPS of $4.84, short of analyst estimates of roughly $4.90 to $4.91. It also cut its 2026 EPS outlook to a range of $15.35 to $15.65, down from $15.55 to $15.95. Globe Life blamed high-severity claims and delayed Medicare claims processing, and its shares dropped 7.74% on Friday. A guidance cut tied to claims trends tends to make investors reassess risk across life and health carriers.
MetLife's 4.67% decline was roughly double the sector's move. That gap suggests profit-taking added to the pressure on a stock that had closed at a 52-week high the day before. The company's own fundamentals going into the session were mixed. Its Q2 results, released on August 5, showed adjusted EPS of $2.43, ahead of the $2.37 estimate and up 20% year over year, with adjusted ROE of 17%. Revenue, however, came in at $19.07 billion against a $19.64 billion consensus. With Q3 results scheduled for November 4, some investors appear to have locked in gains rather than hold a full position into the report during a weak tape for insurers.
What is the MetLife, Inc. Rating - Should I Sell?
Weiss Ratings assigns MET a B rating. Current recommendation is Buy. Friday's decline does not change that assessment. A one-day move driven largely by sector-wide weakness has little bearing on the balance-sheet quality and return record behind the rating.
The foundation of the rating is MetLife's financial strength. The Excellent rating on the Solvency Index matters a great deal for a life insurer, whose business model depends on honoring long-dated obligations to policyholders and annuitants. The Excellent Total Return Index reflects how well the stock has rewarded holders, a record underscored by the fact that MET was trading at its 52-week high only a day before this pullback. Profitability on capital is solid. The Good rating on the Efficiency Index is supported by a 13.09% ROE, a respectable figure for a capital-heavy insurer, and management's 17% adjusted ROE in the latest quarter suggests the underlying business performs better than the reported figure implies. The Good rating on the Volatility Index fits a stock that has generally traded in an orderly way. Friday's sector-driven drop shows why that rating stops short of Excellent.
Where the picture becomes more nuanced is growth and income. Revenue grew 10.46%, but the profit margin is a thin 4.56%. That gap helps explain why the Growth Index is rated only Fair: top-line expansion has not yet produced proportionally stronger earnings. The latest revenue miss against consensus reinforces that caution. The Fair rating on the Dividend Index reflects a 2.24% yield, which is serviceable but modest for a mature insurer. With the stock priced at 19.84 times forward earnings, investors are paying a meaningful premium for EPS of $5.22, so there is less room for disappointment when results land on November 4.
Within the Financials sector, MetLife ranks ahead of The Progressive Corporation (PGR, B-) and Ping An Insurance (Group) Company of China, Ltd. (PNGAY, B-). It trails several insurance peers with stronger profiles in Weiss's framework, including The Allstate Corporation (ALL, A), The Travelers Companies, Inc. (TRV, A+), and Manulife Financial Corporation (MFC, A+). That positioning suggests MetLife is a quality name within the group, though not its top-ranked one.
About MetLife, Inc.
MetLife, Inc. (MET) is a Financials company and one of the largest providers of insurance, annuities, and employee benefit programs in the world. The company is headquartered in New York and traces its roots to 1868. It serves individual and institutional customers across the United States, Asia, Latin America, and Europe, the Middle East and Africa, and its global footprint gives it exposure to both mature and faster-growing insurance markets.
The company's largest U.S. franchise is Group Benefits. Through that business, MetLife sells term life, dental, disability, vision, and accident and health coverage to employers, which offer it to their workforces. Its Retirement & Income Solutions business provides stable value products, pension risk transfer arrangements, structured settlements, and institutional income annuities, which places MetLife at the center of corporate efforts to offload pension obligations. Internationally, the company sells life, health, and savings-oriented products through agency, bancassurance, and direct channels. MetLife Investment Management offers asset management services to institutional clients.
MetLife's competitive advantages come from its scale, its deep relationships with employers, and a brand built over more than 150 years. Its large general account and investment management capabilities let it price long-duration liabilities competitively. Its broad distribution network across the employer market creates sticky, recurring premium income that smaller carriers find difficult to match.
Investor Outlook
MetLife, Inc. (MET) carries a Weiss Rating of B (Buy), and Friday's decline reflects sector-wide pressure and profit-taking more than any break in the company's fundamentals. Investors should watch the November 4 Q3 report for signs that revenue is tracking closer to expectations. They should also watch for any claims trends similar to those that hit Globe Life, as well as the path of Treasury yields, which shape both investment income and sentiment across insurers. See full rankings of all B-rated Financials stocks inside the Weiss Stock Screener.
--